Lineage Cell Therapeutics Inc (AMEX:LCTX)

$ 0.6126 0.0052 (0.86%) Market Cap: 133.88 Mil Enterprise Value: 103.92 Mil PE Ratio: 0 PB Ratio: 1.74 GF Score: 61/100

Q3 2024 Lineage Cell Therapeutics Inc Earnings Call Transcript
Nov 14, 2024

$0.885 (-3.07%)

Earnings
Q2 2024 Lineage Cell Therapeutics Inc Earnings Call Transcript
Aug 08, 2024

$0.8806 (+1.80%)

Earnings
Q4 2023 Lineage Cell Therapeutics Inc Earnings Call Transcript
Mar 07, 2024

$1.13

Earnings
Q3 2023 Lineage Cell Therapeutics Inc Earnings Call Transcript
Nov 09, 2023

$1.07 (-2.73%)

Earnings
Q2 2023 Lineage Cell Therapeutics Inc Earnings Call Transcript
Aug 10, 2023

$1.41 (-2.08%)

Earnings
Q1 2023 Lineage Cell Therapeutics Inc Earnings Call Transcript
May 11, 2023

$1.41 (-1.40%)

Earnings
Q4 2022 Lineage Cell Therapeutics Inc Earnings Call Transcript
Mar 09, 2023

$1.46

Earnings
Q3 2022 Lineage Cell Therapeutics Inc Earnings Call Transcript
Nov 10, 2022

$1.33 (+6.40%)

Earnings
Q2 2022 Lineage Cell Therapeutics Inc Earnings Call Transcript
Aug 11, 2022

$1.55 (-0.64%)

Earnings
Q1 2022 Lineage Cell Therapeutics Inc Earnings Call Transcript
May 12, 2022

$1.18 (-0.84%)

Earnings
Lineage Cell Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 27, 2022
Lineage Cell Therapeutics Inc at Noble Capital Markets Investor Conference (Virtual) Transcript
Apr 20, 2022
Q4 2021 Lineage Cell Therapeutics Inc Earnings Call Transcript
Mar 10, 2022

$1.4 (-1.41%)

Earnings
Lineage Cell Therapeutics Inc To Discuss Worldwide OpRegen Collaboration Call Transcript
Dec 20, 2021
Q3 2021 Lineage Cell Therapeutics Inc Earnings Call Transcript
Nov 10, 2021

$2.36 (-4.45%)

Earnings
Lineage Cell Therapeutics Inc at B Riley Fall Growth Biotech Best Ideas (Virtual) Transcript
Oct 18, 2021
Q2 2021 Lineage Cell Therapeutics Inc Earnings Call Transcript
Aug 12, 2021

$2.61 (-1.51%)

Earnings
Lineage Cell Therapeutics Inc at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 22, 2021
Lineage Cell Therapeutics Inc Webinar Featuring External Therapeutic Area Experts Transcript
Jun 10, 2021
Q1 2021 Lineage Cell Therapeutics Inc Earnings Call Transcript
May 13, 2021

$2.17 (-4.41%)

Earnings
Q4 2020 Lineage Cell Therapeutics Inc Earnings Call Transcript
Mar 11, 2021

$2.34 (+4.00%)

Earnings
Lineage Cell Therapeutics Inc Corporate Analyst Meeting Transcript
Feb 22, 2021
Lineage Cell Therapeutics, Inc. - Special Call Transcript
Nov 17, 2020
Q3 2020 Lineage Cell Therapeutics Inc Earnings Call Transcript
Nov 04, 2020

$1.21 (-0.82%)

Earnings
Q2 2020 Lineage Cell Therapeutics Inc Earnings Call Transcript
Aug 06, 2020

$0.92 (+5.02%)

Earnings
Lineage Cell Therapeutics, Inc. - Special Call Transcript
Jun 08, 2020
Lineage Cell Therapeutics, Inc. - Special Call Transcript
May 11, 2020
Q1 2020 Lineage Cell Therapeutics Inc Earnings Call Transcript
May 07, 2020

$0.957 (+0.21%)

Earnings
Q4 2019 Lineage Cell Therapeutics Inc Earnings Call Transcript
Mar 12, 2020

$0.6801 (-14.10%)

Earnings
Lineage Cell Therapeutics Inc at Solebury Trout KOL Day Transcript
Nov 15, 2019
Q3 2019 Lineage Cell Therapeutics Inc Earnings Call Transcript
Nov 12, 2019

$0.72 (-1.37%)

Earnings
Q2 2019 BioTime Inc Earnings Call Transcript
Aug 08, 2019

$0.99 (-1.98%)

Earnings
Q1 2019 BioTime Inc Earnings Call Transcript
May 09, 2019

$1.18 (-1.67%)

Earnings
Q4 2018 BioTime Inc Earnings Call Transcript
Mar 14, 2019

$1.55 (-1.27%)

Earnings

Q3 2023 Lineage Cell Therapeutics Inc Earnings Call Transcript

Nov 09, 2023 / 09:30PM GMT

Release Date Price: $1.07 (-2.73%)

Transcript 10-Q8-K

Operator

Welcome to the Lineage Cell Therapeutics Third Quarter 2023 Conference Call. (Operator Instructions) An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. (Operator Instructions) As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, Please go ahead.

Ioana C. Hone

Lineage Cell Therapeutics, Inc. - Director of IR

Thank you, Jordan. Good afternoon, and thank you for joining us. A press release reporting our third quarter 2023 financial results was issued earlier today, November 9, 2023, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.